Medication for clinical extensively-drug resistant acinetobacter baumannii

Abstract

A medication for Acinetobacter baumannii infection comprises tetracycline; and a ginger compound, selecting from a group of [6]-dehydrogingerdione, [10]-gingerol, [6]-shogaol and [6]-gingerol. Also, a method for improving tetracycline-resistance of A. baumannii , by providing the ginger compound described above combined with tetracycline to against A. baumannii infection.

1 . A medication for  Acinetobacter baumannii  infection, comprising:
 tetracycline; and   a ginger compound selected from a group of [6]-dehydrogingerdione, [10]-gingerol, [6]-shogaol and [6]-gingerol.   
     
     
         2 . The medication for  Acinetobacter baumannii  infection as defined in  claim 1 , with the tetracycline at a concentration of 25 μg/ml. 
     
     
         3 . The medication for  Acinetobacter baumannii  infection as defined in  claim 1 , with the ginger compound at a concentration of lower than 10 μM and higher than 0 μM. 
     
     
         4 . A method for improving tetracycline-resistance of  Acinetobacter baumannii , by providing the ginger compound as defined in  claim 1  combined with tetracycline to against  A. baumannii  infection. 
     
     
         5 . The method for improving tetracycline-resistance of  Acinetobacter baumannii  as defined in  claim 4 , wherein the ginger compound is at a concentration of lower than 10 μM and higher than 0 μM. 
     
     
         6 . The method for improving tetracycline-resistance of  Acinetobacter baumannii  as defined in  claim 4 , with the tetracycline at a concentration of 25 μg/ml.